Top 3 drug approvals in oncology in April 2022: tepotinib, Enhertu and tislelizumab

In the latest instalment of our oncology drug approval round-up, find out about the approval of tepotinib for METex14 mutated NSCLC, Enhertu for HER2-mutant metastatic NSCLC as well as tislelizumab for certain esophageal squamous cell carcinoma patients. Tepmetko® (tepotinib) Approved: 14 April 2022 Approving body: National Institute for Health and Care Excellence (NICE) Indication: METex14 mutated NSCLC In mid-March Tepmetko® (tepotinib) became the first and only oral MET inhibitor recommended for use in the NHS in England, Wales and Northern Ireland for the treatment of advanced NSCLC with METex14 alterations. The drug, developed by Merck (Darmstadt, Germany), exhibited encouraging results...